Alkermes rises after positive early-stage ADHD drug data
BUZZ-Alkermes rises after positive early-stage ADHD drug data ** Shares of Alkermes ALKS.O rise 7.2% to $46.51 premarket
** Co says experimental ADHD drug, ALKS 7290, reduced symptoms in adults in an early-stage study
** ADHD is a neurodevelopmental disorder that affects brain development and is marked by persistent problems with attention, impulsivity and hyperactivity
** Study enrolled 50 adults who received 20 mg or 50 mg of ALKS 7290, or placebo, for 14 days
** Co says drug showed dose-dependent improvements in ADHD symptoms and disease severity
** On a 54-point scale used to assess ADHD symptoms, patients receiving the 20 mg dose had a median 14-point reduction from baseline after 14 days, while those receiving 50 mg had a 19-point reduction
** Alkermes is enrolling about 312 adults in a mid-stage study testing three dosing regimens against placebo; data expected in 2027
** As of last close, stock up 55.1% YTD
(Reporting by Siddhi Mahatole)